Therapeutic implications of the mGluR theory of fragile X mental retardation

Genes Brain Behav. 2005 Aug;4(6):393-8. doi: 10.1111/j.1601-183X.2005.00135.x.

Abstract

Evidence is reviewed that the consequences of group 1 metabotropic glutamate receptor (Gp1 mGluR) activation are exaggerated in the absence of the fragile X mental retardation protein, likely reflecting altered dendritic protein synthesis. Abnormal mGluR signaling could be responsible for remarkably diverse psychiatric and neurological symptoms in fragile X syndrome, including delayed cognitive development, seizures, anxiety, movement disorders and obesity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Anxiety Disorders / genetics
  • Anxiety Disorders / metabolism
  • Anxiety Disorders / physiopathology
  • Brain / metabolism*
  • Brain / physiopathology
  • Child
  • Developmental Disabilities / genetics
  • Developmental Disabilities / metabolism
  • Developmental Disabilities / physiopathology
  • Epilepsy / genetics
  • Epilepsy / metabolism
  • Epilepsy / physiopathology
  • Fragile X Mental Retardation Protein
  • Fragile X Syndrome / metabolism*
  • Fragile X Syndrome / physiopathology
  • Fragile X Syndrome / therapy
  • Humans
  • Movement Disorders / genetics
  • Movement Disorders / metabolism
  • Movement Disorders / physiopathology
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism*
  • RNA-Binding Proteins / genetics
  • RNA-Binding Proteins / metabolism*
  • Receptors, Metabotropic Glutamate / biosynthesis*

Substances

  • FMR1 protein, human
  • Nerve Tissue Proteins
  • RNA-Binding Proteins
  • Receptors, Metabotropic Glutamate
  • Fragile X Mental Retardation Protein